The global market for Chronic Graft-versus-host Disease (cGVHD) Treatment was estimated to be worth US$ 1425 million in 2023 and is forecast to a readjusted size of US$ 2500.9 million by 2030 with a CAGR of 8.3% during the forecast period 2024-2030

Chronic Graft-versus-host Disease (cGVHD) Treatment - Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Chronic Graft-versus-host Disease (cGVHD) Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Chronic Graft-versus-host Disease (cGVHD) Treatment by region & country, by Type, and by Application.

The Chronic Graft-versus-host Disease (cGVHD) Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Graft-versus-host Disease (cGVHD) Treatment.

Market Segmentation

Scope of Chronic Graft-versus-host Disease (cGVHD) Treatment - Market Report

Report Metric	Details
Report Name	Chronic Graft-versus-host Disease (cGVHD) Treatment - Market
Forecasted market size in 2030	US$ 2500.9 million
CAGR	8.3%
Forecasted years	2024 - 2030
Segment by Type:	Corticosteroids mTOR Inhibitors Tyrosine Kinase Inhibitors Monoclonal Antibodies Others
Segment by Application	Hospitals Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Merck KGaA, Sanofi SA, Novartis AG, Bristol Myers Squibb, Pfizer, Roche Holding AG, Johnson & Johnson, Eli Lilly and Company, Abbott Laboratories, Takeda Pharmaceutical Company
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Chronic Graft-versus-host Disease (cGVHD) Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Chronic Graft-versus-host Disease (cGVHD) Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Chronic Graft-versus-host Disease (cGVHD) Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Chronic Graft-versus-host Disease (cGVHD) Treatment - Market size in 2030?

Ans: The Chronic Graft-versus-host Disease (cGVHD) Treatment - Market size in 2030 will be US$ 2500.9 million.

Who are the main players in the Chronic Graft-versus-host Disease (cGVHD) Treatment - Market report?

Ans: The main players in the Chronic Graft-versus-host Disease (cGVHD) Treatment - Market are Merck KGaA, Sanofi SA, Novartis AG, Bristol Myers Squibb, Pfizer, Roche Holding AG, Johnson & Johnson, Eli Lilly and Company, Abbott Laboratories, Takeda Pharmaceutical Company

What are the Application segmentation covered in the Chronic Graft-versus-host Disease (cGVHD) Treatment - Market report?

Ans: The Applications covered in the Chronic Graft-versus-host Disease (cGVHD) Treatment - Market report are Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Chronic Graft-versus-host Disease (cGVHD) Treatment - Market report?

Ans: The Types covered in the Chronic Graft-versus-host Disease (cGVHD) Treatment - Market report are Corticosteroids, mTOR Inhibitors, Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Others

1 Market Overview

1.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Product Introduction

1.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Market Size Forecast

1.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Trends & Drivers

1.3.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Industry Trends

1.3.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Drivers & Opportunity

1.3.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Challenges

1.3.4 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Players Revenue Ranking (2023)

2.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue by Company (2019-2024)

2.3 Key Companies Chronic Graft-versus-host Disease (cGVHD) Treatment Manufacturing Base Distribution and Headquarters

2.4 Key Companies Chronic Graft-versus-host Disease (cGVHD) Treatment Product Offered

2.5 Key Companies Time to Begin Mass Production of Chronic Graft-versus-host Disease (cGVHD) Treatment

2.6 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Competitive Analysis

2.6.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Corticosteroids

3.1.2 mTOR Inhibitors

3.1.3 Tyrosine Kinase Inhibitors

3.1.4 Monoclonal Antibodies

3.1.5 Others

3.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type

3.2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, by Type (2019-2030)

3.2.3 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospitals Pharmacies

4.1.2 Retail Pharmacies

4.1.3 Online Pharmacies

4.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application

4.2.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, by Application (2019-2030)

4.2.3 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Region

5.1.1 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Region (2019-2024)

5.1.3 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Region (2025-2030)

5.1.4 Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

5.2.2 North America Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

5.3.2 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

5.4.2 Asia Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

5.5.2 South America Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

5.6.2 Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value

6.3 United States

6.3.1 United States Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

6.3.2 United States Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

6.4.2 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

6.5.2 China Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

6.5.3 China Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

6.6.2 Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

6.7.2 South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

6.8.2 Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019-2030

6.9.2 India Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

6.9.3 India Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Merck KGaA

7.1.1 Merck KGaA Profile

7.1.2 Merck KGaA Main Business

7.1.3 Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

7.1.4 Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (US$ Million) & (2019-2024)

7.1.5 Merck KGaA Recent Developments

7.2 Sanofi SA

7.2.1 Sanofi SA Profile

7.2.2 Sanofi SA Main Business

7.2.3 Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

7.2.4 Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (US$ Million) & (2019-2024)

7.2.5 Sanofi SA Recent Developments

7.3 Novartis AG

7.3.1 Novartis AG Profile

7.3.2 Novartis AG Main Business

7.3.3 Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

7.3.4 Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (US$ Million) & (2019-2024)

7.3.5 Bristol Myers Squibb Recent Developments

7.4 Bristol Myers Squibb

7.4.1 Bristol Myers Squibb Profile

7.4.2 Bristol Myers Squibb Main Business

7.4.3 Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

7.4.4 Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (US$ Million) & (2019-2024)

7.4.5 Bristol Myers Squibb Recent Developments

7.5 Pfizer

7.5.1 Pfizer Profile

7.5.2 Pfizer Main Business

7.5.3 Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

7.5.4 Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (US$ Million) & (2019-2024)

7.5.5 Pfizer Recent Developments

7.6 Roche Holding AG

7.6.1 Roche Holding AG Profile

7.6.2 Roche Holding AG Main Business

7.6.3 Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

7.6.4 Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (US$ Million) & (2019-2024)

7.6.5 Roche Holding AG Recent Developments

7.7 Johnson & Johnson

7.7.1 Johnson & Johnson Profile

7.7.2 Johnson & Johnson Main Business

7.7.3 Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

7.7.4 Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (US$ Million) & (2019-2024)

7.7.5 Johnson & Johnson Recent Developments

7.8 Eli Lilly and Company

7.8.1 Eli Lilly and Company Profile

7.8.2 Eli Lilly and Company Main Business

7.8.3 Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

7.8.4 Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (US$ Million) & (2019-2024)

7.8.5 Eli Lilly and Company Recent Developments

7.9 Abbott Laboratories

7.9.1 Abbott Laboratories Profile

7.9.2 Abbott Laboratories Main Business

7.9.3 Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

7.9.4 Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (US$ Million) & (2019-2024)

7.9.5 Abbott Laboratories Recent Developments

7.10 Takeda Pharmaceutical Company

7.10.1 Takeda Pharmaceutical Company Profile

7.10.2 Takeda Pharmaceutical Company Main Business

7.10.3 Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

7.10.4 Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue (US$ Million) & (2019-2024)

7.10.5 Takeda Pharmaceutical Company Recent Developments

8 Industry Chain Analysis

8.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Industrial Chain

8.2 Chronic Graft-versus-host Disease (cGVHD) Treatment Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Model

8.5.2 Sales Channel

8.5.3 Chronic Graft-versus-host Disease (cGVHD) Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Eli Lilly and Company

Abbott Laboratories

Takeda Pharmaceutical Company

List of Tables

Table 1. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Trends

Table 2. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Drivers & Opportunity

Table 3. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Challenges

Table 4. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Restraints

Table 5. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Chronic Graft-versus-host Disease (cGVHD) Treatment Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Chronic Graft-versus-host Disease (cGVHD) Treatment Product Type

Table 9. Key Companies Time to Begin Mass Production of Chronic Graft-versus-host Disease (cGVHD) Treatment

Table 10. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Graft-versus-host Disease (cGVHD) Treatment as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Region (2019-2024) & (%)

Table 27. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, (2025-2030) & (US$ Million)

Table 31. Merck KGaA Basic Information List

Table 32. Merck KGaA Description and Business Overview

Table 33. Merck KGaA Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

Table 34. Revenue (US$ Million) in Chronic Graft-versus-host Disease (cGVHD) Treatment Business of Merck KGaA (2019-2024)

Table 35. Merck KGaA Recent Developments

Table 36. Sanofi SA Basic Information List

Table 37. Sanofi SA Description and Business Overview

Table 38. Sanofi SA Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

Table 39. Revenue (US$ Million) in Chronic Graft-versus-host Disease (cGVHD) Treatment Business of Sanofi SA (2019-2024)

Table 40. Sanofi SA Recent Developments

Table 41. Novartis AG Basic Information List

Table 42. Novartis AG Description and Business Overview

Table 43. Novartis AG Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

Table 44. Revenue (US$ Million) in Chronic Graft-versus-host Disease (cGVHD) Treatment Business of Novartis AG (2019-2024)

Table 45. Novartis AG Recent Developments

Table 46. Bristol Myers Squibb Basic Information List

Table 47. Bristol Myers Squibb Description and Business Overview

Table 48. Bristol Myers Squibb Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

Table 49. Revenue (US$ Million) in Chronic Graft-versus-host Disease (cGVHD) Treatment Business of Bristol Myers Squibb (2019-2024)

Table 50. Bristol Myers Squibb Recent Developments

Table 51. Pfizer Basic Information List

Table 52. Pfizer Description and Business Overview

Table 53. Pfizer Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

Table 54. Revenue (US$ Million) in Chronic Graft-versus-host Disease (cGVHD) Treatment Business of Pfizer (2019-2024)

Table 55. Pfizer Recent Developments

Table 56. Roche Holding AG Basic Information List

Table 57. Roche Holding AG Description and Business Overview

Table 58. Roche Holding AG Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

Table 59. Revenue (US$ Million) in Chronic Graft-versus-host Disease (cGVHD) Treatment Business of Roche Holding AG (2019-2024)

Table 60. Roche Holding AG Recent Developments

Table 61. Johnson & Johnson Basic Information List

Table 62. Johnson & Johnson Description and Business Overview

Table 63. Johnson & Johnson Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

Table 64. Revenue (US$ Million) in Chronic Graft-versus-host Disease (cGVHD) Treatment Business of Johnson & Johnson (2019-2024)

Table 65. Johnson & Johnson Recent Developments

Table 66. Eli Lilly and Company Basic Information List

Table 67. Eli Lilly and Company Description and Business Overview

Table 68. Eli Lilly and Company Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

Table 69. Revenue (US$ Million) in Chronic Graft-versus-host Disease (cGVHD) Treatment Business of Eli Lilly and Company (2019-2024)

Table 70. Eli Lilly and Company Recent Developments

Table 71. Abbott Laboratories Basic Information List

Table 72. Abbott Laboratories Description and Business Overview

Table 73. Abbott Laboratories Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

Table 74. Revenue (US$ Million) in Chronic Graft-versus-host Disease (cGVHD) Treatment Business of Abbott Laboratories (2019-2024)

Table 75. Abbott Laboratories Recent Developments

Table 76. Takeda Pharmaceutical Company Basic Information List

Table 77. Takeda Pharmaceutical Company Description and Business Overview

Table 78. Takeda Pharmaceutical Company Chronic Graft-versus-host Disease (cGVHD) Treatment Products, Services and Solutions

Table 79. Revenue (US$ Million) in Chronic Graft-versus-host Disease (cGVHD) Treatment Business of Takeda Pharmaceutical Company (2019-2024)

Table 80. Takeda Pharmaceutical Company Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Chronic Graft-versus-host Disease (cGVHD) Treatment Downstream Customers

Table 84. Chronic Graft-versus-host Disease (cGVHD) Treatment Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Chronic Graft-versus-host Disease (cGVHD) Treatment Product Picture

Figure 2. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 4. Chronic Graft-versus-host Disease (cGVHD) Treatment Report Years Considered

Figure 5. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Chronic Graft-versus-host Disease (cGVHD) Treatment Revenue in 2023

Figure 7. Chronic Graft-versus-host Disease (cGVHD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Corticosteroids Picture

Figure 9. mTOR Inhibitors Picture

Figure 10. Tyrosine Kinase Inhibitors Picture

Figure 11. Monoclonal Antibodies Picture

Figure 12. Others Picture

Figure 13. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 14. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value Market Share by Type, 2023 & 2030

Figure 15. Product Picture of Hospitals Pharmacies

Figure 16. Product Picture of Retail Pharmacies

Figure 17. Product Picture of Online Pharmacies

Figure 18. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 19. Global Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value Market Share by Application, 2023 & 2030

Figure 20. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 21. North America Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 22. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 23. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 24. Asia Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 25. Asia Pacific Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 26. South America Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 27. South America Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 28. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value (2019-2030) & (US$ Million)

Figure 29. Middle East & Africa Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Country (%), 2023 VS 2030

Figure 30. Key Countries/Regions Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value (%), (2019-2030)

Figure 31. United States Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 32. United States Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 33. United States Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 34. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 35. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 36. Europe Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 37. China Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 38. China Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 39. China Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 40. Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 41. Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 42. Japan Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 43. South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 44. South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 45. South Korea Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 46. Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 47. Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 48. Southeast Asia Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 49. India Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 50. India Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Type (%), 2023 VS 2030

Figure 51. India Chronic Graft-versus-host Disease (cGVHD) Treatment Sales Value by Application (%), 2023 VS 2030

Figure 52. Chronic Graft-versus-host Disease (cGVHD) Treatment Industrial Chain

Figure 53. Chronic Graft-versus-host Disease (cGVHD) Treatment Manufacturing Cost Structure

Figure 54. Channels of Distribution (Direct Sales, and Distribution)

Figure 55. Bottom-up and Top-down Approaches for This Report

Figure 56. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Clotting Factors Ⅷ Market Insights, Forecast to 2030

120 Pages

Type: Report

Code: QYRE-Auto-21S8513

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Rare Genetic Disease Diagnosis Solution - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-17L15214

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Endoscopes for Otology - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-19V14797

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Immunotherapy Drugs for Neuroblastoma - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-39R14639

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions